Short answer
LifeMD, Inc. (LFMD) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Disclosure concerns LifeMD’s planned AT&T strategic collaboration and anticipated commercial benefits.
LifeMD, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Disclosure concerns LifeMD’s planned AT&T strategic collaboration and anticipated commercial benefits
- Program launch timing, pricing, availability, and expansion remain subject to execution and adoption risks
- Telehealth controlled-substance prescribing laws and compliance requirements create material regulatory uncertainty
- Investors should assess final program scope and patient demand against LifeMD’s forward-looking assumptions
Item EX-99.1 · Exhibit EX-99.1
- Exclusive AT&T collaboration gives over 100 million eligible wireless and fiber customers complimentary LifeMD access
- Waived $19 monthly membership equals $228 annual value, while customers still pay for visits, prescriptions, and services
- Initial rollout reaches 29 million customers across 11 states, with nationwide expansion planned for January 2027
- Customer acquisition opportunity across virtual care, pharmacy, chronic conditions, GLP-1 weight management, and specialty services
- Visits priced from $29 message-based care to $79 specialty care, supporting usage-based revenue beyond membership fees
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LifeMD, Inc. 8-K filings
Get the next LFMD 8-K as it lands
Follow LFMD for push alerts, or ask the research agent what this filing means.